Stroke survivors miss critical treatment, face greater disability due to systemic transfer delays

Patients who have longer delays in hospital transfer experienced worse disability after their stroke

5:00 AM

Author | Noah Fromson

blur of hospital staff moving patient in on stretcher
Getty Images

Gaps in the nation’s stroke transfer system are drastically reducing survivors’ chances of receiving critical treatment and increasing the likelihood that they will leave the hospital with a disability, a study suggests.

Around one-third of ischemic stroke survivors are eligible for endovascular thrombectomy, an effective intervention that changed the landscape of stroke treatment more than a decade ago.

More than 40% of people who receive endovascular therapy are initially seen at hospitals that don’t offer the treatment.

These patients require transfer to more advanced facilities capable of delivering thrombectomy. 

The findings published in The Lancet Neurology led by investigators from University of Michigan and the University of Chicago reveal that the vast majority of stroke patients face prolonged time to transfer — a process known as door-in-door-out — which reduces their chance of receiving endovascular therapy and increases their chances of leaving the hospital with significant disability.

“This is all about getting people to the right care at the right time,” said Regina Royan, M.D., M.P.H., co-first author and Assistant Professor of Emergency Medicine and Neurology at U-M Medical School.

“Endovascular therapy has been a revolutionary treatment for acute ischemic stroke for years, but a significant portion of patients experience substantial delays in receiving this therapy. Our results show that the stroke transfer system, at a national level, is falling short for patients.”

Systemic issues in the stroke transfer system

In the study of more than 20,000 patients with acute ischemic stroke, researchers found that just 26% of transfers occurred within 90 minutes, the maximum time recommended by the American Heart Association.

The likelihood of a patient receiving endovascular therapy declined steeply as transfer time delays grew.

Patients with transfer times between 91 minutes and three hours had 29% less chance of receiving a thrombectomy.

That number climbed to 65% when the door-in-door-out time was longer than 4.5 hours.

“We have made tremendous progress in getting people timely acute stroke treatment after they arrive at the emergency department, which we call door-to-needle time, but the next frontier of acute stroke systems of care is improving inter-hospital transfer times for patients eligible for endovascular thrombectomy,” said Shyam Prabhakaran, M.D., M.S., senior author and Chair of Neurology at the University of Chicago.

“Every minute that passes before treatment increases the risk of losing neurologic functioning, and our results highlight missed opportunities for many stroke patients who are not initially seen at thrombectomy-capable centers.”

Stroke patients with longer door-in-door-out times had higher scores on the modified Rankin scale, a measure of overall disability used in clinical research.

They also had more complications after treatment and a lower likelihood of being able to walk independently after leaving the hospital.

Improving the system

The team’s findings on the systemic delays in hospital transfer, which relied on data from the AHA’s Get With the Guidelines-Stroke registry, reinforces their work from 2023.

According to the registry’s earlier data from more than 1,900 hospitals, the median door-in-door-out time for stroke patients was nearly three hours.

This national study, however, is the largest examination of the relationship between those delays, missed opportunities for endovascular therapy and worse functional outcomes in acute ischemic stroke patients.

Systemic changes are especially important for areas with larger rural populations and those lacking formal stroke systems of care.

“With this study, we now have compelling evidence that we need to be paying greater attention to developing efficiencies within regional stroke systems of care with a targeted focus on minimizing door-in-door-out times,” said Brian Stamm, M.D., M.Sc., co-first author and Clinical Assistant Professor of Neurology at University of Michigan Medical School.

“We have seen successful global quality improvement initiatives reduce door-to-needle times for clot-busting medications. We should use those as a roadmap to do the same for reducing door-in-door-out time for inter-hospital stroke transfers.”

An ongoing NIH-sponsored clinical trial led by Prabhakaran, called Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition (HI-SPEED), is testing whether an intervention to reduce door-in-door-out times at eight large health systems around the United States will improve functional outcomes for acute ischemic stroke patients undergoing thrombectomy. 

U-M is one of the trial sites, with emergency physician William J. Meurer, M.D., serving as site principal investigator and Stamm serving as site co-investigator.

The researchers also note the need for ongoing research aimed at the prehospital window before a patient is brought to the hospital.

“Having prehospital tools that effectively identify patients who are more likely to receive endovascular therapy and triage them to thrombectomy-capable centers that provide that care is another way besides door-in-door-out interventions that we can increase access to this highly effective procedure.” Royan said. 

Additional authors: Mihai Giurcanu, Ph.D., of University of Chicago, Steven R Messe, M.D., of University of Pennsylvania, Edward C Jauch, M.D., M.S., of Mountain Area Health Education Center, and Jeffrey L Saver, M.D., of University of California Los Angeles.

Funding/disclosures: This study was partially supported by the National Institute of Neurological Disorders and Stroke (K12NS137516, U24NS107233, R25NS125609, U01NS131797) and the Agency for Healthcare Research and Quality (R18HS027264) of the National Institutes of Health.

The GWTG Stroke program is provided by the American Heart Association. GWTG-Stroke is sponsored, in part, by Novartis, Novo Nordisk, AstraZeneca, Bayer, and HCA Healthcare.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or AHA.

Paper cited “Door-in-door-out times and outcomes in patients with acute ischaemic stroke transferred for endovascular therapy: a retrospective US cohort study,” The Lancet Neurology. DOI: 10.1016/S1474-4422(25)00478-8

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week.

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows.  


More Articles About:

stroke Cardiovascular: Diseases & Conditions Stroke Treatment Cardiovascular: Treatment & Surgery Emergency & Trauma Care All Research Topics
Health Lab word mark overlaying blue cells

Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Brian Stamm

Brian Stamm, M,D,, MSc

Clinical Assistant Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast

Medicare's New GLP-1 Bridge Program

An obesity expert welcomes new Medicare option for access to effective weight loss medication, and shares the new program’s limitations.
close up of cells blue purple pink
Health Lab

Researchers create new path to target hard-to-drug prostate cancer protein

University of Michigan researchers have identified a specific pocket within ERG, a driver of prostate cancer, and have developed a small molecule probe, called PBITE-1, that can bind to it.
team standing around person using virtual reality headset
Health Lab

How new care models, within a new building launch, are helping optimize patient care

New care models in a new building opening at Michigan Medicine is helping to optimize patient care.
Health Lab

Path forward for glioblastoma treatment

Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment
doctor in white coat with heart model in hand in hallway looking down
Health Lab

How a temporary heart pump can support high risk cardiac surgery

A cardiac surgeon from Michigan Medicine offers helpful details on Impella devices.
lights scattered all over blue screen connected
Health Lab

Studying neurons using neurons

Labs at the University of Michigan Medical School are exploring a new technology that leverages the biological capabilities of human neurons for artificial intelligence.